

Gerard Lozanski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4834999/publications.pdf>

Version: 2024-02-01

86
papers

3,784
citations

236925

25
h-index

133252

59
g-index

89
all docs

89
docs citations

89
times ranked

4556
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 770-773.	3.5	10
2	Prevalence of current and past COVID-19 in Ohio adults. <i>Annals of Epidemiology</i> , 2022, 67, 50-60.	1.9	1
3	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	12.4	150
4	Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2. <i>Cell Host and Microbe</i> , 2022, 30, 1093-1102.e3.	11.0	114
5	Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL Patient Data Registry (PDR) analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7577-7577.	1.6	1
6	Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7540-7540.	1.6	2
7	Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease. <i>Vaccines</i> , 2021, 9, 555.	4.4	3
8	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. <i>Leukemia</i> , 2021, 35, 3406-3420.	7.2	3
9	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. <i>Blood</i> , 2021, 137, 3473-3483.	1.4	40
10	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021, 12, 700045.	4.8	2
11	Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. <i>MBio</i> , 2021, 12, e0251021.	4.1	33
12	Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism. <i>Blood</i> , 2021, 138, 4297-4297.	1.4	0
13	CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies. <i>Blood</i> , 2021, 138, 889-889.	1.4	3
14	A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3728-3728.	1.4	2
15	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	1.4	27
16	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). <i>Haematologica</i> , 2021, 106, 2834-2844.	3.5	3
17	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
18	LC-FACSeq is a method for detecting rare clones in leukemia. <i>JCI Insight</i> , 2020, 5, .	5.0	6

#	ARTICLE	IF	CITATIONS
19	Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight, 2020, 5, .	5.0	86
20	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	12
21	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	1.4	1
22	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. Kidney International Reports, 2019, 4, 1152-1160.	0.8	44
23	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood, 2019, 133, 2765-2775.	1.4	63
24	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 2018, 103, 982-987.	3.5	16
25	A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters. Cytometry Part B - Clinical Cytometry, 2018, 94, 239-249.	1.5	34
26	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia and Lymphoma, 2018, 59, 1008-1011.	1.3	29
27	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
28	Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology. PLoS ONE, 2018, 13, e0196547.	2.5	7
29	Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images. PLoS ONE, 2018, 13, e0196846.	2.5	39
30	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	1.4	18
31	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 2018, 132, 1859-1859.	1.4	1
32	Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events. Blood, 2018, 132, 1845-1845.	1.4	0
33	Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. Blood, 2018, 132, 2305-2305.	1.4	11
34	Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. Blood, 2018, 132, 4143-4143.	1.4	1
35	Computer-assisted quantification of CD3+ T cells in follicular lymphoma. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 609-621.	1.5	5
36	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193

#	ARTICLE	IF	CITATIONS
37	BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. <i>Blood Advances</i> , 2017, 1, 2147-2160.	5.2	5
38	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016, 128, 1050-1058.	1.4	74
39	Granulocyte Colony-Stimulating Factor- Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 658-668.	2.0	23
40	MuCor: mutation aggregation and correlation. <i>Bioinformatics</i> , 2016, 32, 1557-1558.	4.1	17
41	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 71-79.	2.0	11
42	BRAFV600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia. <i>Blood</i> , 2016, 128, 1206-1206.	1.4	3
43	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	1.4	25
44	Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance. <i>Blood</i> , 2016, 128, 2907-2907.	1.4	2
45	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , 2016, 128, 4386-4386.	1.4	2
46	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388.	1.4	2
47	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	1.4	17
48	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
49	Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5598-5598.	1.4	3
50	SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model. <i>Blood</i> , 2016, 128, 580-580.	1.4	1
51	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
52	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	1.4	0
53	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3409-3409.	1.4	0
54	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3410-3410.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts. <i>Blood</i> , 2016, 128, 4598-4598.	1.4	0
56	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. <i>Blood</i> , 2016, 128, 1346-1346.	1.4	12
57	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 242-248.	1.4	124
58	Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood</i> , 2015, 126, 842-850.	1.4	125
59	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. <i>Haematologica</i> , 2015, 100, e18-e20.	3.5	7
60	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
61	Classification of follicular lymphoma: the effect of computer aid on pathologists grading. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 115.	3.0	30
62	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2015, 90, 967-969.	4.1	2
63	The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. <i>Oncotarget</i> , 2015, 6, 2693-2708.	1.8	23
64	The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. <i>Cancer Immunology Research</i> , 2015, 3, 787-794.	3.4	23
65	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. <i>Leukemia Research</i> , 2015, 39, 1270-1277.	0.8	11
66	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
67	Hypermorphic mutation of phospholipase C, $\hat{1}^2$ acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. <i>Blood</i> , 2015, 126, 61-68.	1.4	141
68	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	1.4	2
69	Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 9-13.	4.9	26
70	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	1.4	56
71	Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. <i>Journal of Pathology Informatics</i> , 2013, 4, 30.	1.7	20
72	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , 2013, 122, 2872-2872.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012, 53, 1743-1748.	1.3	16
74	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. <i>Cancer Cell</i> , 2012, 21, 694-708.	16.8	122
75	Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2012, 120, 1949-1949.	1.4	0
76	An Image Analysis Approach for Detecting Malignant Cells in Digitized H&E-stained Histology Images of Follicular Lymphoma. , 2010, , .		9
77	Histopathological Image Analysis Using Model-Based Intermediate Representations and Color Texture: Follicular Lymphoma Grading. <i>Journal of Signal Processing Systems</i> , 2009, 55, 169-183.	2.1	163
78	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1232-1234.	1.3	0
79	Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression.. <i>Blood</i> , 2009, 114, 1737-1737.	1.4	0
80	Texture classification using nonlinear color quantization: Application to histopathological image analysis. <i>Proceedings of the IEEE International Conference on Acoustics, Speech, and Signal Processing</i> , 2008, , .	1.8	34
81	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.. <i>Blood</i> , 2007, 110, 2073-2073.	1.4	1
82	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. <i>Blood</i> , 2007, 110, 3104-3104.	1.4	3
83	The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL.. <i>Blood</i> , 2007, 110, 3123-3123.	1.4	1
84	CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights.. <i>Blood</i> , 2006, 108, 2293-2293.	1.4	3
85	Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.. <i>Blood</i> , 2006, 108, 302-302.	1.4	6
86	Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. <i>Blood</i> , 2004, 103, 3278-3281.	1.4	370